Skip to main content
Top
Published in: Journal of Translational Medicine 1/2014

Open Access 01-12-2014 | Research

Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis

Authors: Hui-wei Qi, Ling-yan Xin, Xin Xu, Xian-xiu Ji, Li-hong Fan

Published in: Journal of Translational Medicine | Issue 1/2014

Login to get access

Abstract

Background

The effects of berberine on the metastatic potential of lung cancer cells and its underlying mechanisms have not been fully elucidated. Since epithelial-to-mesenchymal transition is a cellular process associated with cancer invasion and metastasis, we attempted to investigate the potential use of berberine as an inhibitor of TGF-β1-induced epithelial-to-mesenchymal in A549 cells.

Methods

In this study, we investigated the anticancer activity of berberine against A549 cells in vitro and in vivo. BBR-induced apoptosis of the human lung cancer cells was determined by flow cytometry. The ability of BBR to inhibit TGF-β-induced EMT was examined by QRT-PCR and Western blotting. The impact of BBR on A549 cell migration and invasion was evaluated by transwell assay.

Results

We demonstrated that TGF-β1 induced epithelial-to-mesenchymal to promote lung cancer invasion and metastasis. Berberine inhibited invasion and migration of A549 cells, increased expression of the epithelial phenotype marker E-cadherin, repressed the expression of the mesenchymal phenotype marker Vimentin, as well as decreased the level of epithelial-to-mesenchymal -inducing transcription factors Snail1 and Slug during the initiation of TGF-β1-induced epithelial-to-mesenchymal. Furthermore, berberine inhibited growth of lung cancer cells in vivo xenograft.

Conclusions

Our findings provided new evidence that berberine is an effective inhibitor of the metastatic potential of A549 cells through suppression of TGF-β1-induced epithelial-to-mesenchymal.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRef Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRef
2.
go back to reference Laverty HG, Wakefield LM, Occleston NL, O'Kane S, Ferguson MW: TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev. 2009, 20 (4): 305-317. 10.1016/j.cytogfr.2009.07.002.CrossRefPubMed Laverty HG, Wakefield LM, Occleston NL, O'Kane S, Ferguson MW: TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev. 2009, 20 (4): 305-317. 10.1016/j.cytogfr.2009.07.002.CrossRefPubMed
3.
go back to reference Tian M, Neil JR, Schiemann WP: Transforming growth factor-beta and the hallmarks of cancer. Cell Signal. 2011, 23 (6): 951-962. 10.1016/j.cellsig.2010.10.015.PubMedCentralCrossRefPubMed Tian M, Neil JR, Schiemann WP: Transforming growth factor-beta and the hallmarks of cancer. Cell Signal. 2011, 23 (6): 951-962. 10.1016/j.cellsig.2010.10.015.PubMedCentralCrossRefPubMed
4.
go back to reference Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139 (5): 871-890. 10.1016/j.cell.2009.11.007.CrossRefPubMed Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 2009, 139 (5): 871-890. 10.1016/j.cell.2009.11.007.CrossRefPubMed
5.
go back to reference Wu YY, Peck K, Chang YL, Pan SH, Cheng YF, Lin JC, Yang RB, Hong TM, Yang PC: SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene. 2011, 30 (34): 3682-3693. 10.1038/onc.2011.85.CrossRefPubMed Wu YY, Peck K, Chang YL, Pan SH, Cheng YF, Lin JC, Yang RB, Hong TM, Yang PC: SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene. 2011, 30 (34): 3682-3693. 10.1038/onc.2011.85.CrossRefPubMed
6.
go back to reference Tirino V, Camerlingo R, Bifulco K, Irollo E, Montella R, Paino F, Sessa G, Carriero MV, Normanno N, Rocco G, Pirozzi G: TGF-beta1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death & Disease. 2013, 4: e620-10.1038/cddis.2013.144.CrossRef Tirino V, Camerlingo R, Bifulco K, Irollo E, Montella R, Paino F, Sessa G, Carriero MV, Normanno N, Rocco G, Pirozzi G: TGF-beta1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death & Disease. 2013, 4: e620-10.1038/cddis.2013.144.CrossRef
7.
go back to reference Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2 (6): 442-454. 10.1038/nrc822.CrossRefPubMed Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002, 2 (6): 442-454. 10.1038/nrc822.CrossRefPubMed
8.
go back to reference Wendt MK, Schiemann WP: Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res. 2009, 11 (5): R68-10.1186/bcr2360.PubMedCentralCrossRefPubMed Wendt MK, Schiemann WP: Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res. 2009, 11 (5): R68-10.1186/bcr2360.PubMedCentralCrossRefPubMed
9.
go back to reference Hills CE, Squires PE: TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2010, 31 (1): 68-74. 10.1159/000256659.CrossRefPubMed Hills CE, Squires PE: TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2010, 31 (1): 68-74. 10.1159/000256659.CrossRefPubMed
10.
go back to reference Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, Lee YM, Moon DC, Han SB, Hong JT: Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol. 2009, 34 (5): 1221-1230.PubMed Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, Lee YM, Moon DC, Han SB, Hong JT: Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol. 2009, 34 (5): 1221-1230.PubMed
11.
go back to reference Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H: Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther. 2011, 10 (8): 1346-1356. 10.1158/1535-7163.MCT-10-0985.PubMedCentralCrossRefPubMed Li J, Cao B, Liu X, Fu X, Xiong Z, Chen L, Sartor O, Dong Y, Zhang H: Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther. 2011, 10 (8): 1346-1356. 10.1158/1535-7163.MCT-10-0985.PubMedCentralCrossRefPubMed
12.
go back to reference Liu B, Wang G, Yang J, Pan X, Yang Z, Zang L: Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLoS One. 2011, 6 (6): e21416-10.1371/journal.pone.0021416.PubMedCentralCrossRefPubMed Liu B, Wang G, Yang J, Pan X, Yang Z, Zang L: Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLoS One. 2011, 6 (6): e21416-10.1371/journal.pone.0021416.PubMedCentralCrossRefPubMed
13.
14.
go back to reference Tsang CM, Lau EP, Di K, Cheung PY, Hau PM, Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, Tsao SW, Feng Y: Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med. 2009, 24 (1): 131-138.PubMed Tsang CM, Lau EP, Di K, Cheung PY, Hau PM, Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, Tsao SW, Feng Y: Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med. 2009, 24 (1): 131-138.PubMed
15.
go back to reference Li-Weber M: Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2013, 332 (2): 304-312. 10.1016/j.canlet.2010.07.015.CrossRefPubMed Li-Weber M: Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2013, 332 (2): 304-312. 10.1016/j.canlet.2010.07.015.CrossRefPubMed
16.
go back to reference Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010, 70 (23): 9895-9904. 10.1158/0008-5472.CAN-10-1546.PubMedCentralCrossRefPubMed Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010, 70 (23): 9895-9904. 10.1158/0008-5472.CAN-10-1546.PubMedCentralCrossRefPubMed
17.
go back to reference Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E(2) and prostaglandin E(2) receptors. Carcinogenesis. 2011, 32 (1): 86-92. 10.1093/carcin/bgq215.PubMedCentralCrossRefPubMed Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E(2) and prostaglandin E(2) receptors. Carcinogenesis. 2011, 32 (1): 86-92. 10.1093/carcin/bgq215.PubMedCentralCrossRefPubMed
18.
go back to reference Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang HI, Wang CJ, Yang SF, Liou YS, Kuo WH: Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL. Arch Toxicol. 2007, 81 (10): 719-728. 10.1007/s00204-006-0169-y.CrossRefPubMed Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang HI, Wang CJ, Yang SF, Liou YS, Kuo WH: Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL. Arch Toxicol. 2007, 81 (10): 719-728. 10.1007/s00204-006-0169-y.CrossRefPubMed
19.
go back to reference Meeran SM, Katiyar S, Katiyar SK: Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol. 2008, 229 (1): 33-43. 10.1016/j.taap.2007.12.027.CrossRefPubMed Meeran SM, Katiyar S, Katiyar SK: Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol. 2008, 229 (1): 33-43. 10.1016/j.taap.2007.12.027.CrossRefPubMed
20.
go back to reference Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB: Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008, 68 (13): 5370-5379. 10.1158/0008-5472.CAN-08-0511.CrossRefPubMed Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB: Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008, 68 (13): 5370-5379. 10.1158/0008-5472.CAN-08-0511.CrossRefPubMed
21.
go back to reference Katiyar SK, Meeran SM, Katiyar N, Akhtar S: p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog. 2009, 48 (1): 24-37. 10.1002/mc.20453.CrossRefPubMed Katiyar SK, Meeran SM, Katiyar N, Akhtar S: p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog. 2009, 48 (1): 24-37. 10.1002/mc.20453.CrossRefPubMed
22.
go back to reference Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003, 425 (6958): 577-584. 10.1038/nature02006.CrossRefPubMed Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003, 425 (6958): 577-584. 10.1038/nature02006.CrossRefPubMed
23.
go back to reference Grycova L, Dostal J, Marek R: Quaternary protoberberine alkaloids. Phytochemistry. 2007, 68 (2): 150-175. 10.1016/j.phytochem.2006.10.004.CrossRefPubMed Grycova L, Dostal J, Marek R: Quaternary protoberberine alkaloids. Phytochemistry. 2007, 68 (2): 150-175. 10.1016/j.phytochem.2006.10.004.CrossRefPubMed
24.
go back to reference Imanshahidi M, Hosseinzadeh H: Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008, 22 (8): 999-1012. 10.1002/ptr.2399.CrossRefPubMed Imanshahidi M, Hosseinzadeh H: Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008, 22 (8): 999-1012. 10.1002/ptr.2399.CrossRefPubMed
25.
go back to reference Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y: Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009, 126 (1): 5-17. 10.1016/j.jep.2009.08.009.CrossRefPubMed Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y: Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009, 126 (1): 5-17. 10.1016/j.jep.2009.08.009.CrossRefPubMed
26.
go back to reference Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY: Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol. 2006, 80 (2): 62-73. 10.1007/s00204-005-0014-8.CrossRefPubMed Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY: Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol. 2006, 80 (2): 62-73. 10.1007/s00204-005-0014-8.CrossRefPubMed
27.
go back to reference Jantova S, Letasiova S, Brezova V, Cipak L, Labaj J: Photochemical and phototoxic activity of berberine on murine fibroblast NIH-3 T3 and Ehrlich ascites carcinoma cells. J Photochem Photobiol B. 2006, 85 (3): 163-176. 10.1016/j.jphotobiol.2006.07.001.CrossRefPubMed Jantova S, Letasiova S, Brezova V, Cipak L, Labaj J: Photochemical and phototoxic activity of berberine on murine fibroblast NIH-3 T3 and Ehrlich ascites carcinoma cells. J Photochem Photobiol B. 2006, 85 (3): 163-176. 10.1016/j.jphotobiol.2006.07.001.CrossRefPubMed
28.
go back to reference Mantena SK, Sharma SD, Katiyar SK: Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006, 5 (2): 296-308. 10.1158/1535-7163.MCT-05-0448.CrossRefPubMed Mantena SK, Sharma SD, Katiyar SK: Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006, 5 (2): 296-308. 10.1158/1535-7163.MCT-05-0448.CrossRefPubMed
29.
go back to reference Wang GY, Lv QH, Dong Q, Xu RZ, Dong QH: Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. J Asian Nat Prod Res. 2009, 11 (3): 219-228. 10.1080/10286020802675076.CrossRefPubMed Wang GY, Lv QH, Dong Q, Xu RZ, Dong QH: Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. J Asian Nat Prod Res. 2009, 11 (3): 219-228. 10.1080/10286020802675076.CrossRefPubMed
30.
go back to reference Hamsa TP, Kuttan G: Berberine inhibits pulmonary metastasis through down-regulation of MMP in metastatic B16F-10 melanoma cells. Phytother Res. 2012, 26 (4): 568-578. 10.1002/ptr.3586.CrossRefPubMed Hamsa TP, Kuttan G: Berberine inhibits pulmonary metastasis through down-regulation of MMP in metastatic B16F-10 melanoma cells. Phytother Res. 2012, 26 (4): 568-578. 10.1002/ptr.3586.CrossRefPubMed
31.
go back to reference Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL: TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011, 71 (13): 4707-4719. 10.1158/0008-5472.CAN-10-4554.PubMedCentralCrossRefPubMed Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL: TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011, 71 (13): 4707-4719. 10.1158/0008-5472.CAN-10-4554.PubMedCentralCrossRefPubMed
32.
go back to reference Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C: IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011, 71 (15): 5296-5306. 10.1158/0008-5472.CAN-11-0156.PubMedCentralCrossRefPubMed Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C: IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011, 71 (15): 5296-5306. 10.1158/0008-5472.CAN-11-0156.PubMedCentralCrossRefPubMed
33.
go back to reference Yadav A, Kumar B, Datta J, Teknos TN, Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011, 9 (12): 1658-1667. 10.1158/1541-7786.MCR-11-0271.PubMedCentralCrossRefPubMed Yadav A, Kumar B, Datta J, Teknos TN, Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011, 9 (12): 1658-1667. 10.1158/1541-7786.MCR-11-0271.PubMedCentralCrossRefPubMed
34.
go back to reference Chen XF, Zhang HJ, Wang HB, Zhu J, Zhou WY, Zhang H, Zhao MC, Su JM, Gao W, Zhang L, Fei K, Zhang HT, Wang HY: Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep. 2012, 39 (4): 3549-3556. 10.1007/s11033-011-1128-0.CrossRefPubMed Chen XF, Zhang HJ, Wang HB, Zhu J, Zhou WY, Zhang H, Zhao MC, Su JM, Gao W, Zhang L, Fei K, Zhang HT, Wang HY: Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep. 2012, 39 (4): 3549-3556. 10.1007/s11033-011-1128-0.CrossRefPubMed
35.
go back to reference Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT: Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA. 2010, 107 (6): 2485-2490. 10.1073/pnas.0908133107.PubMedCentralCrossRefPubMed Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT: Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA. 2010, 107 (6): 2485-2490. 10.1073/pnas.0908133107.PubMedCentralCrossRefPubMed
36.
go back to reference Zhang HJ, Wang HY, Zhang HT, Su JM, Zhu J, Wang HB, Zhou WY, Zhang H, Zhao MC, Zhang L, Chen XF: Transforming growth factor-beta1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition. Mol Cell Biochem. 2011, 355 (1–2): 309-314.CrossRefPubMed Zhang HJ, Wang HY, Zhang HT, Su JM, Zhu J, Wang HB, Zhou WY, Zhang H, Zhao MC, Zhang L, Chen XF: Transforming growth factor-beta1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition. Mol Cell Biochem. 2011, 355 (1–2): 309-314.CrossRefPubMed
37.
go back to reference Vandenbroucke RE, Dejonckheere E, Libert C: A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?. Eur Respir J. 2011, 38 (5): 1200-1214. 10.1183/09031936.00027411.CrossRefPubMed Vandenbroucke RE, Dejonckheere E, Libert C: A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?. Eur Respir J. 2011, 38 (5): 1200-1214. 10.1183/09031936.00027411.CrossRefPubMed
38.
go back to reference Chetty C, Rao JS, Lakka SS: Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics. 2011, 12 (4): 535-546. 10.2217/pgs.10.207.CrossRefPubMed Chetty C, Rao JS, Lakka SS: Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics. 2011, 12 (4): 535-546. 10.2217/pgs.10.207.CrossRefPubMed
39.
go back to reference Nistico P, Bissell MJ, Radisky DC: Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol. 2012, 4: 2-CrossRef Nistico P, Bissell MJ, Radisky DC: Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol. 2012, 4: 2-CrossRef
40.
go back to reference Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med. 2000, 342 (18): 1350-1358. 10.1056/NEJM200005043421807.CrossRefPubMed Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med. 2000, 342 (18): 1350-1358. 10.1056/NEJM200005043421807.CrossRefPubMed
Metadata
Title
Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis
Authors
Hui-wei Qi
Ling-yan Xin
Xin Xu
Xian-xiu Ji
Li-hong Fan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2014
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-12-22

Other articles of this Issue 1/2014

Journal of Translational Medicine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.